Nyxoah (NYXH) Q4 2025 earnings review
Stellar U.S. Launch Crushes Guidance, But Cash Burn Remains in Focus
Nyxoah delivered an explosive Q4, with revenue accelerating to €5.64 million (+347% YoY)—massively beating the €3.4-€3.6 million guidance provided in Q3. This surge was driven by the first full quarter of U.S. commercialization of the Genio system following its August FDA approval. The company activated 57 U.S. accounts and trained 145 surgeons, rapidly breaking into a market previously dominated by a single incumbent. However, scaling the 50-person commercial organization came at a cost: Operating loss for FY25 reached €83.5 million. While the company's Q3 financing package provides runway, managing the €48.0 million year-end cash balance against an expanding U.S. footprint remains the primary execution challenge.
🐂 Bull Case
The U.S. launch is drastically outperforming expectations. Delivering €5.6M in Q4 vs a €3.4-3.6M guide demonstrates extremely high physician enthusiasm and an efficient conversion from surgeon training (145 trained) to active implants (57 accounts).
Management successfully leveraged the existing CPT code 64568. Genio is being consistently reimbursed by major commercial payors and Medicare, removing the biggest traditional hurdle for medtech product launches.
🐻 Bear Case
Cash, equivalents, and financial assets stood at €48.0 million at year-end. With an FY25 operating loss of €83.5 million and SG&A set to scale further, the cash burn requires careful management despite late 2025 financing efforts.
Gross margin came in at 64% for Q4, down from 73% a year ago. Management previously signaled that target margins of 80%+ will not be achieved until late 2026/2027 with higher volumes and the Genio 2.2 rollout.
⚖️ Verdict: 🟢
Bullish. The Q4 revenue beat is a definitive proof-of-concept that Nyxoah's differentiated technology (bilateral stimulation, battery-free) is rapidly stealing mindshare in a major market. The immediate sequential growth guidance further de-risks the commercial trajectory.
Key Themes
U.S. Launch Momentum is Accelerating
Nyxoah's two-pronged U.S. strategy (targeting 400 high-volume incumbent centers and building new sleep referral networks) is bearing fruit faster than expected. Q4 net revenue jumped 347% YoY to €5.6 million. Getting 57 accounts activated within roughly four months of launch proves that the 'optionality' narrative—offering ENTs a choice beyond the legacy single-player market—is resonating.
Elevated Cash Burn Profile
While revenue is scaling, operating leverage remains negative. Selling, General, and Administrative expenses were €12.5 million in Q4 (up from €8.1M in 24Q4) to support the U.S. sales force. The total FY25 net loss of €90.1 million highlights the heavy capital intensity of launching a Class III medical device nationwide. The year-end cash balance of €48.0 million means investors must closely monitor the burn rate.
De-risked Market Access and Reimbursement
A key concern ahead of the launch was reimbursement friction. Q4 results confirmed this risk has been largely mitigated. Management reported that the Genio system is being consistently reimbursed by Medicare and major commercial payors, utilizing the established CPT code 64568. This frictionless payment pathway is a massive catalyst for driving immediate physician adoption.
Inspire Medical Litigation Overhang
Nyxoah is currently defending against a patent infringement lawsuit filed by incumbent Inspire Medical in May 2025. While management has stated they will 'vigorously defend' themselves and counter-sued in September 2025, this ongoing litigation represents a distraction and a persistent legal expense that will weigh on SG&A.
Product Differentiation Proving Itself
The rapid Q4 adoption serves as clinical and commercial validation for Genio's unique design. The lack of an implanted battery (eliminating replacement surgeries) and the bilateral stimulation protocol are clear selling points. Furthermore, the GLP-1 weight-loss tailwind—which management notes helps bring patients down to Genio's proven sub-32 BMI efficacy range—appears to be expanding the addressable funnel rather than cannibalizing it.
Other KPIs
Stable sequentially compared to Q3's 60.5%, but down from 73% in 24Q4. The year-over-year compression is attributed to initial ramp-up operational activities and early supply chain inefficiencies for the U.S. launch. Expanding this toward the 80% long-term target remains a multi-year execution story.
Accelerating from €34.3 million in FY24. Driven by continued clinical expansion initiatives—including the ACCCESS study for Complete Concentric Collapse (CCC) patients—and ongoing product development for the next-generation Genio 2.2 platform.
Expanding year-over-year from €17.1 million in 24Q4, but remarkably stable on a sequential basis vs Q3's €23.6 million loss, indicating that the massive Q4 revenue surge flowed through the P&L without requiring an unexpected proportional spike in sequential OPEX.
Guidance
Accelerating dollar growth. Guiding to a 25% increase over Q4's already massive beat implies strong compounding momentum. Assuming the vast majority of Q4's €5.6M was U.S. driven, this implies roughly €7.0M+ in total Q1 revenue.
Accelerating. Projecting another 25% compounding sequential step-up in Q2 demonstrates extreme confidence in the backlog of VAC (Value Analysis Committee) approvals and the pacing of new territory managers gaining hospital access.
Key Questions
Pacing of Territory Managers
With 57 accounts activated already, what is the current headcount of your U.S. commercial organization, and what is the pacing for adding new territory managers through 2026 to hit your coverage targets?
Gross Margin Trajectory
Gross margins have settled in the low-to-mid 60s. Can you provide a bridge outlining how much volume scale vs. the launch of the Genio 2.2 system is required to push margins toward the 80% long-term target?
Cash Burn and Operating Leverage
With the first $26M tranche of the convertible bond secured in Q3 and €48M on the balance sheet, when do you project the company will hit peak quarterly cash burn, considering the rapid revenue ramp we are seeing?
Competitive Response
As you break into these top 400 high-volume sites, are you seeing any changes in commercial behavior, pricing, or contracting strategies from the incumbent?